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HypofractionationAbstract Aims and background: Reduction of overall treatment time of postoperative irradiation
and evaluation of the feasibility and preliminary toxicity of an accelerated hypofractionated whole
breast irradiation with an addition of a concomitant daily boost in patients with early breast cancer
submitted to conservation surgery.
Materials: Between June 2010 and September 2011, 122 patients underwent accelerated hypofrac-
tionated adjuvant radiation after conservation surgery (pT1 or pT2, pN0-N1). Radiotherapy con-
sisted of 45 Gy, to the whole breast in 20 fractions with 2.25 Gy/fraction; an additional daily boost
dose of 0.25 Gy was concomitantly delivered to the lumpectomy cavity, total dose 5 Gy. Toxicity
was assessed at the end of radiation therapy and at 3, 6, and 12 months using the RTOG/EORTC
toxicity scale. Cosmetic results were assessed in agreement with the Harvard criteria.
Results: Median follow-up was 31 months, 74% showed grade 0–1 skin toxicity, 20% grade 2, and
6% grade 3. At 3 months of follow-up, grade 0 skin toxicity was observed in 51% of cases; grade 1
in 36%, and grade 2 in 13%. At 6 months, late skin and subcutaneous tissue toxicities were scored
as grade 0 in 71%, grade 1 in 18%, and grade 2 in 11% of patients.
At 1 year almost all the patients showed grade 0–1 skin toxicity. 97% of patients showed excellent
or good cosmetic results.
Conclusions: Accelerated hypofractionated radiotherapy for early breast cancer with concomitant
electron boost seems to be feasible providing consistent clinical results with acceptable toxicity pro-
ﬁle.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Worldwide, breast cancer is the most common cancer among
females. The American Cancer Society estimates that 234,190
Americans will be diagnosed with invasive breast cancer and
10,730 will die of the disease in the United States in 2015 [1].
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breast irradiation (AWBI) remains the standard of care for
early stage breast cancer. In a large metaanalysis, BCS was
associated with a proven local control beneﬁt and a gain in
overall survival [2].
In addition, randomized clinical trials showed that a boost
after whole-breast irradiation further improved local control.
Consequently, boost RT is a widely accepted practice in
patients at a higher risk of local recurrence, particularly
younger patients, and those with close surgical margins. The
updated results of the European Organization for Research
and Treatment of Cancer (EORTC) 22,881 study, with a med-
ian follow-up of 10.8 years, demonstrated a highly signiﬁcant
reduction in local recurrence rates for patients randomized to
a sequential boost of 16 Gy in 8 fractions, compared to those
receiving no boost (6.2% vs. 10.2%, p< 0.0001) [3]. However,
the rate of severe ﬁbrosis in those receiving a boost was
increased (4.4% vs. 1.6%, p< 0.0001).
Similarly, Romestaing et al. reported that an additional
10 Gy boost in ﬁve fractions was associated with decreased
ﬁve-year local recurrence rates (3.6% vs. 4.5%, p= 0.044),
however, this was associated with an increased rate of grades
1 and 2 telangiectasias (12.4% vs. 5.9%) [4].
The optimal dose, fractionation schedule, methods of deliv-
ery, and timing of the boost, remains as yet undeﬁned.
Although many centers have adopted hypofractionated breast
radiotherapy as the standard for whole breast irradiation
(WBI), it is still unclear how best to incorporate a boost into
this hypofractionated schema, particularly from a radiobiolog-
ical perspective. Three of four large randomized trials allowed
a sequential boost, which typically consisted of ﬁve conven-
tional fractions of 2 Gy each delivered with en face electrons
[5–8].
In our study, we present the preliminary results in feasibil-
ity, toxicity, and cosmesis obtained from 122 patients treated
with hypofractionated WBI with a daily concomitant boost
(CB) regimen.Patients and methods
One hundred and twenty-two consecutive patients with opera-
ble early-stage invasive breast cancer were treated at Tanta
University hospital with hypofractionated External Beam
Radiation Therapy (EBRT) as part of their breast conserva-
tion treatment (BCT) between June 2010 and September 2011.
Eligibility criteria for this protocol were histologically
proved adenocarcinoma of the breast; prior BCS (namely
lumpectomy or quadrantectomy); pathological stage, pT1 or
pT2, pN0–1 according to America Joint Committee on Cancer
(AJCC) (seventh edition) [9]; no clinical evidence of distant
metastases at diagnosis.
Exclusion criteria included carcinoma in situ, locally
advanced or metastatic disease, prior radiation to the thoracic
region, active connective tissue disease, age >80 years, the
synchronous ﬁnding of a second primary tumor, pregnancy
or the presence of a concomitant psychiatric disorder preclud-
ing an aware informed consent. Patients with large breasts
(separation is greater than 25 cm, that is, the breast measured
more than 25 cm left to right at its widest part) were also
excluded [7,10]. All patients provided written informed consent
before starting treatment.Radiation therapy was planned immediately after BCS in
low-risk patients or sequentially after chemotherapy (CT) in
those at higher risk of failure. Prognostic classes were assigned
according to the St. Gallen Consensus Conference [11].
This protocol has been submitted and approved by our
institutional ethics committee.
Volumes of interest and treatment planning
A planning CT scan was carried out for each patient from the
level of the larynx to the upper abdomen including the bases of
both lungs with the patient in the supine position on a ‘‘wing-
board” with both arms raised above the head. Scan thickness
was 5 mm. Radiopaque wires and markers were used to locate
palpable breast tissue and visible surgical scars. Three tattoos
were made on the thoracic skin to enable patient repositioning
during treatment.
The CT data were transferred to the Eclipse Treatment
Planning System (Varian, Palo Alto, CA, USA). The Whole
Breast Clinical Target Volume (WB-CTV) included glandular
breast tissue but exclude the pectoralis major, the ribs and
the skin. The Whole Breast Planning Target Volume (WB-
PTV) was generated by adding a 3-D 5 mm margin around
the WB-CTV while a 10 mm margin was used for the cranial
and caudal directions. The deﬁnition of the lumpectomy cavity
was guided by the presence of surgical clips, seroma, hema-
toma, or other surgery-induced changes considered to be part
of the cavity. The concomitant boost CTV (CB-CTV) was gen-
erated by adding at least a 10 mm margin around the lumpec-
tomy cavity and the corresponding concomitant boost PTV
(CB-PTV) was created by adding a further 5 mm 3 D margin
around CB-CTV. The heart and ipsilateral lung were consid-
ered organs at risks (OARs). The ipsilateral lung was con-
toured in all its extension. The heart was contoured from the
pulmonary trunks superiorly to its base and included the peri-
cardium. The major blood vessels were excluded.
Treatment planning
The WB-PTV was covered by two opposing tangential beams.
A multi-leaf collimator (MLC) was used to spare OARs. The
appropriate gantry angles were determined in order to achieve
maximal avoidance of the heart, ipsilateral lung and contralat-
eral breast. A boost plan was created conformal to the CB-
PTV, using an electron ﬁeld. Wedge and MLC shielding were
selected in order to obtain a 95% isodose encompassing the
boost PTV. A cumulative dose-volume histogram was created
to evaluate dose distribution to WB-PTV, CB-PTV, and OARs
and accept the proposed plan.
Radiation fractionation and treatment
The basic course for adjuvant whole breast irradiation con-
comitant boost (AWBI-CB) consisted of 45 Gy, prescribed to
the ICRU reference point dose delivered to the whole breast
in 20 fractions with 2.25 Gy/fraction with two opposing
6 MV tangential ﬁeld; an additional electron dose boost of
0.25 Gy was concomitantly delivered, on a daily basis, to the
lumpectomy cavity (CB-PTV), for a total additional dose of
5 Gy. The cumulative nominal dose was 50 Gy delivered in
four weeks with a daily dose of 2.5 Gy. Finally, the isocenter
Table 1 Patient demographics, disease characteristics and
therapy.
Characteristics Patients (%)
Age
650 48 (39)
>50 74 (61)
Tumor class (AJCC)
pT1a 2 (2)
pT1b 8 (6)
pT1c 6 (9)
pT2 101 (83)
Grading
G1 12 (10)
G2 90 (74)
G3 20 (16)
Molecular characteristics
Estrogen receptors
pos 90 (74)
neg 32 (26)
Progesterone receptors
pos 88 (72)
neg 34 (28)
HER 2
neg 98 (80)
pos 24 (20)
KI-67
620 84 (69)
>20 38 (31)
Surgical margins
Negative 116 (95)
Positive/Close 6 (5)
Nodal status
pN0 72 (59)
pN1 50 (41)
Histology
Ductal carcinoma 95 (78)
Lobular carcinoma 17 (14)
Others 10 (8)
Treatment
Previous chemotherapy or MoAb 98 (80)
FEC for six cycles 41 (34)
CMF-based 7 (6)
FEC three cycles + TXT three cycles 32 (26)
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and the boost plan.
Portal ﬁlms of the whole breast were taken at least once
during the ﬁrst day of irradiation and compared with Digitally
Reconstructed Radiographs (DRRs) for matching.
Radiobiological equivalent dose
With the aim of comparing the conventionally fractionated
sequential boost schedule, consisting of 60 Gy in 30 fractions,
with the concomitant boost accelerated hypofractionated
whole-breast radiotherapy employed in the present study
(a total of 50 Gy given in 20 fractions), a conversion into a bio-
logically effective dose (BED) was performed, according to the
linear quadratic model formalism [12].
For this calculation, we assumed an a/b ratio of 4 Gy for
tumor response, 10 Gy for acute responding normal tissues,
3 Gy for late-responding tissues. The biological comparison
between the standard and the explored RT schedule is shown
in Table 2.
Follow-up
Clinical visits were performed every week during the treatment
course and at the end of treatment. In the follow-up, patients
were checked at 1, 3, 6 months and at one year after the end of
treatment. A mammographic examination was planned
6–8 months after the end of radiotherapy.
Hormone treatment, when indicated, was discontinued
during the radiotherapy regimen.
Evaluation of toxicity and cosmesis
To determine the severity and incidence of acute and short-
term late toxicities with the AWBI-CB technique, patients were
evaluated. Acute toxicity was assessed at the end of radiother-
apy and at three months after the treatment course, whereas
late toxicity was scored at 6 months and at one year after the
end the treatment. The maximal toxicity was scored using
the Common Terminology Criteria for Adverse Events,
version 3.010, using the RTOG/EORTC toxicity scale as-
associated with radiation as reference [13]. This resulted in a
toxicity grade for each patient. Cosmesis was assessed at one
year using a cosmetic scale of excellent, good, fair or poor,
in agreement with the Harvard criteria [14].
Physicians were asked to judge the cosmetic results as fol-
lows: an ‘‘excellent” cosmetic result score was assigned when
the treated breast looked essentially the same as the contralat-
eral breast; a ‘‘good” cosmetic score was assigned for minimal
but identiﬁable radiation effects of the treated breast; a ‘‘fair”
score meant signiﬁcant radiation effects were readily observ-
able; a ‘‘poor” score was used for radiation-induced severe late
effects of breast tissue.
The toxicity parameters include erythema, hyperpigmenta-
tion, desquamation, breast edema, ulceration, telangiectasia,
ﬁbrosis, retraction, hypopigmentation, and atrophy.Herceptin 14 (11)
Others 4 (3)
Hormone therapy
Tamoxifene-based 54 (44)
Aromatasis inhibitor-based 37 (30)Results
At the time of reporting, 122 patients had achieved a minimum
follow-up of 12 months (median follow-up 31 months, range12–40 months). All accrued patients were included in this anal-
ysis. Patient demographics, disease characteristics, and therapy
are displayed in Table 1. Most patients (83%) had tumor size
more than two 2 cm and 72 patients (59%) were node negative.
Fourteen patients (11%) received trastuzumab while 74%
received adjuvant hormonal treatment either tamoxifen or
aromatase inhibitors. All patients completed the radiation
therapy course as planned without interruption.
The mean PTV of the whole breast volume was 890
± 220 ccs, the mean PTV of the boost volume was 67
± 29 ccs.
Table 2 Biological comparison between standard adjuvant radiotherapy schedule and explored AWBI-CB schedule.
Adjuvant radiotherapy Basic course and boost delivery BED
Late eﬀects
(a/b= 3 Gy)
Acute eﬀects
(a/b= 10 Gy)
Tumor control
(a/b= 4 Gy)
Standard schedule
60 Gy/30 fx/6 w
WBI basic course: 50 Gy in 25 fx over 5 weeks
+ sequential boost: 10 Gy in 5 fx over 1 week
100 72 90
Explored AWBI-CB
schedule 50 Gy/20 fx
WBI basic course 45 Gy in 20 fx over 4 weeks
+ daily concomitant boost 0.25 Gy daily
91.5 62.5 81
Diﬀerence in dose (%) 8.5 14 10
Table 3 Acute toxicity, late toxicity and cosmetic results.
Morbidity score Time of clinical assessment Patients (%)
RTOG/EORTC
acute toxicity
At treatment completion
Grade
0 28 (23)
1 62 (51)
2 24 (20)
3 8 (6)
RTOG/EORTC
acute toxicity
3 months after AWB-RT
Grade
0 62 (51)
1 44 (36)
2 16 (13)
3 0 (0)
RTOG/EORTC
late toxicity
6 months after AWB-RT
Grade
0 87 (71)
1 22 (18)
2 13 (11)
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Four clinical examinations were performed by a group of inde-
pendent physicians at different time points: ﬁrst at the end of
treatment, then after 3 and 6 months and ﬁnally at 1 year.
As shown in Table 3, at the end of the AWB-RT, 74%
showed grade 0–1 skin toxicity, 20% grade 2, and 6% grade 3.
At 3 months of follow-up, grade 0 skin toxicity was
observed in 51% of cases; grade 1 in 36%, and grade 2 in
13% of patients.
At 6 months, late skin and subcutaneous tissue toxicities
were scored as grade 0 in 71%, grade 1 in 18%, and grade 2
in 11% of patients.
Those results were conﬁrmed also at 1 year with almost all
the patients showing grade 0–1 skin toxicity.
No major lung and heart toxicities could be detected. Cos-
metic result was assessed and scored at 6 months and 1 year
with 97% of patients showed excellent or good cosmetic result.
With a median follow-up of 31 months, 2 patients devel-
oped local recurrence and four patients developed distant
metastases (three in the bone, and one in the lung). The
three-year disease-free survival was 96.5%.3 0 (0)
Harvard cosmesis scale 6 months AWB-RT
Excellent 79 (65)
Good 37 (30)
Fair 5 (4)
Poor 1 (1)
RTOG/EORTC
late toxicity
1 year after AWB-RT
Grade
0 84 (69)
1 32 (26)
2 6 (5)
3 0 (0)
Harvard cosmesis scale 1 year after AWB-RT
Excellent 78 (64)
Good 40 (33)
Fair 4 (3)
Poor 0 (0)
AWB-RT, adjuvant whole-breast radiotherapy; RTOG, Radiation
Therapy Oncology Group; EORTC, European Organization for
Research and Treatment of Cancer.Discussion
Hypofractionation is highly beneﬁcial both for patient conve-
nience and economically for radiation departments due to the
frequency of breast cancer and the shortage of radiation equip-
ment, especially in developing countries. Hypofractionated
schedules have been established as an alternative in numerous
trials; hence hypofractionation for adjuvant breast irradiation
in early breast cancer has been adopted by institutes such as
the UK National Institute for Health and Clinical Excellence
(NICE) as the standard of care [15].
However, boost fractionation is not as standardized. In
order to maximize the beneﬁt of the shortened overall time
in the schedules using fewer fractions, a concurrent boost is
an appealing alternative to sequential boost. There is limited
data experience with accelerated whole-breast radiotherapy
and a concomitant boost, mostly from single institution studies
[16].
Through empiric observation, it has become clear that the
therapeutic ratio, the balance between tumor cell kill and nor-
mal tissue damage, is affected not only by fraction size but also
the total dose of radiation and in some instances overall treat-
ment time and the volume of tissue irradiated. Radiobiological
models have been developed in an attempt to predict improve-
ment in the therapeutic ratio through manipulation of thesedifferent variables. The most commonly used model is the
linear-quadratic equation; it predicts that the biological effect
of radiation will be directly proportional to total dose and
fraction size [17].
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with our schedule comprising the WBI and CB techniques
compares favorably with the standard fractionation dose
adopted in breast management (biologically equivalent dose
(BED) for late response with an a/b= 3, 91.5 Gy vs.
100 Gy; BED for acute response with an a/b= 10, 62.5 Gy
vs. 72 Gy; BED for tumor response with an a/b= 4, 81 Gy
vs. 90 Gy).
The AWBI-CB schedule is less toxic than the standard
schedule with respect to acute effects and late effect (14%
and 9.5% in dose percentage respectively) while our schedule
is slightly less effective with respect to breast tumor control
in the linear-quadratic model (10% in dose percentage).
However, in a clinical context where the a/ß ratios of the
tumor and surrounding normal tissues almost merge (such as
in breast cancer), a larger fraction size, with a simultaneous
slender decrease of the total nominal dose, might be able to
obtain at least a comparable (some would say even higher)
tumor control with the same rate of expected late effects [18].
The treatment course we explored in the present study con-
sists of an accelerated hypofractionation of 20 fractions deliv-
ered to the whole breast with a simultaneous daily boost; dose
per fraction accounts for 2.25 Gy to the whole breast up to a
total nominal dose of 45 Gy; in addition, an electron boost
dose of 0.25 Gy is delivered on a daily basis to the surgical
bed to a total dose of 5 Gy. Boost dose is traditionally deliv-
ered sequentially to whole-breast radiation therapy; however,
we applied this daily concomitant schedule, as it allows for a
substantial reduction in overall treatment time which, along
with an increased dose per fraction to the tumor bed, might
lead to an improved local control [19].
This concept is strictly related to the one intrinsic to the
simultaneous integrated boost (SIB) where whole-breast radio-
therapy and boost dose are integrated into a single plan that
allows for a differential dose delivery to the two volumes
within the same treatment fractions (conversely our planning
procedure provided two different plans for the two volumes).
SIB utilization combined with 3DCRT has proven to improve
conformality to the surgical bed and to decrease heart and
lungs dose if compared with sequential boost [20]. Moreover,
SIB combined with inverse planned intensity modulated
radiotherapy (IMRT) increased tumor bed conformality
and decreased normal tissue dose if compared with
3DCRT-planned sequential boost [21,22]. As a result of the
afore-mentioned background, SIB has been included in the
recent European breast tumor bed boost trial comparing
16 Gy with 26 Gy in patients 650 years [23].
The schedule was adopted for 122 consecutive patients who
met the eligibility criteria. The clinical outcomes presented here
clearly conﬁrm the feasibility of this schedule in the treatment
of patients submitted to RT after conservation surgery. Specif-
ically, all the patients concluded their treatment in the planned
overall time of 4 weeks. Twelve months after the end of radio-
therapy, only six patients (5%) experienced G2 toxicity
according to the RTOG/EORTC classiﬁcation.
Although 8 patients experienced G3 acute toxicity at the
end of RT, no patient had G3 late toxicity after 12 months.
In the 24 women with G2 toxicity at the last fraction of radio-
therapy, local side-effects were not evident in the AWBI-CB
area but were frequently observed either in axillary area or
in the lower border of the breast. Even if the assessment of
cosmesis at 12 months may be considered only a surrogateend-point of long-term cosmesis, at that time an excellent or
good score was reported for 97% of patients. To date, no
patient has relapsed in the breast or loco-regional lymph node
areas.
These results were similar to those reported in an Italian
study that employed a radiation schedule consisting of 46 Gy
delivered over 20 fractions (2.3 Gy daily) with a concomitant
boost dose to the surgical cavity given on a weekly basis
(1.2 Gy once a week up to a total boost dose of 6 Gy), allowing
for a shortening of the overall treatment time: cosmetic results
of 176 patients evaluated 6 months after AWB-RT were
judged excellent/good in 95% of the patients; 5% of the
patients were scored as fair [24].
Chadha et al. [16] reported acute toxicity in the ﬁrst 50
patients enrolled in a prospective trial compared to a control
group treated conventionally. The whole breast dose was
2.7 Gy per fraction in 15 fractions to a total dose of 40.5 Gy
with a concomitant boost dose of 0.3 Gy per fraction to a total
dose of 45 Gy. Both 3D-CRT and IMRT were used in the
reported study. There was a lower incidence of grade 2 skin
toxicity with the concurrent boost (4% vs. 24%, p= 0.0015)
and a lower incidence of breast pain (p= 0.045), which the
authors attributed as secondary to skin toxicity. No difference
was noted on the incidence of breast edema. The authors
attributed the decrease in skin toxicity in the group treated
with hypofractionation to the lower total dose of radiation
and the majority of patients on the concurrent schedule
received IMRT and integrated photon boost instead of an elec-
tron boost, which might have improved acute skin toxicity.
There were no acute grade 3 or 4 toxicities.
In another Italian study [17], Guenzi et al. reported the
results of 65 consecutive patients with operable invasive early
breast cancer treated with a hypofractionated schedule of
External Beam Radiation Therapy. The patient received
39 Gy in 13 fractions in 3 weeks to the whole breast, plus a
weekly concomitant boost dose to the lumpectomy cavity
3 Gy in 3 fractions. With a median follow-up of 24 months,
at three months after treatment 62% presented grade 0 acute
toxicity 29% had grade 1 and 9% had grade 2. This is consis-
tent with our results. At 6 months with all the patients assessed
there was 34% case of grade 1 subacute toxicity and 6% of
grade 2. At 12 months, 43% and 3% of patients presented with
clinical grade 1 and grade 2 ﬁbrosis respectively and 5% pre-
sented grade 1 hyperpigmentation. The remaining patients
were free of side effects.Conclusions
The aim of our study was to determine the acute and late tox-
icities and feasibility of a course of radiation administered in
hypofractionation. The clinical results observed in 122 consec-
utive patients with a median follow-up of 31 months (range
12–40 months) demonstrated a reasonably good feasibility of
the schedule in terms of acute and subacute toxicities as well
as in terms of compliance to treatment. The initial analysis
of late effects appears equally promising. At the moment, this
more convenient 20 fraction schedule seems an acceptable
alternative to the traditional 30-day regime.
Longer follow-up is being arranged to conﬁrm these results
and to evaluate whether this schedule assures excellent local–
regional disease control besides good tolerability.
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